SCHEMBL14701538

SCHEMBL14701538

CC(=O)C[C@H](NC(=O)CN=[N+]=[N-])c1ccc(O)cc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ESR1 P03372 2/20 0.33
ESR2 Q92731 2/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
KMT2A Q03164 2/20 0.33
KEAP1 Q14145 2/20 0.33
NFE2L2 Q16236 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.33
GPR88 Q9GZN0 1/20 0.32
POLB P06746 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14703882 0.87 POLB (0.38) ALDH1A1SMN1; SMN2LMNAMAPTL3MBTL1
SCHEMBL15918765 0.85 GPR88 (0.40) ALDH1A1SMN1; SMN2LMNAESR1ESR2
SCHEMBL16190536 0.81 HTT (0.42) ALDH1A1SMN1; SMN2LMNAMAPTL3MBTL1
SCHEMBL14703881 0.77 ITGB3 (0.46) ALDH1A1SMN1; SMN2LMNAL3MBTL1KEAP1
SCHEMBL14703913 0.77 ITGB3 (0.46) ALDH1A1SMN1; SMN2LMNAL3MBTL1KEAP1
SCHEMBL14703888 0.76 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAMAPTKMT2A
SCHEMBL14701541 0.76 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAMAPTKMT2A
SCHEMBL14703893 0.75 TACR3 (0.44) ALDH1A1SMN1; SMN2LMNAMAPTL3MBTL1
SCHEMBL15918766 0.75 CA2 (0.34) CA2CA9
SCHEMBL14701536 0.75 SLC6A9 (0.49) ALDH1A1SMN1; SMN2LMNAKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809338-B2 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) 2014-08-19 US disclosed
US-20130040964-A1 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) 2013-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040964-A1 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS ICAM1, ITGB3, VCAM1 ALDH1A1 368/4885SMN1; SMN2 4428/4885LMNA 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.